Should I buy Regeneron Pharmaceuticals (REGN) stock or is it too late?

Regeneron Pharmaceuticals · Health Care · price $808

See the full Regeneron Pharmaceuticals (REGN) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $758 (-6.2 %), call made on August 1, 2026, maturing on August 1, 2027 (27 d ago).

The 8 reliable analysts $765-5.3 %

The 9 other firms $875+8.3 %

How to read it: the 8 reliable firms are not filtered by optimism — 3 aim above the price, 5 below, hence their $765 median. “The 9 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Regeneron Pharmaceuticals

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
B of A Securities	80 %	+42.8 %	15	$860 +6%
Citigroup	75 %	+22.2 %	8	$740 -8%
BMO Capital	77 %	+18.6 %	13	$730 -10%
Argus Research	75 %	+17.6 %	8	$1,170 +45%
Oppenheimer	79 %	+16.2 %	14	$865 +7%
Guggenheim	70 %	+16.2 %	10	$1,030 +28%
HC Wainwright & Co.	80 %	+13.6 %	5	$844 +4%
Morgan Stanley	79 %	+12.5 %	19	$758 -6%

In short — Should you invest in Regeneron Pharmaceuticals? Is it too late, still worth it? Analysts are fairly positive (71% buy, median target $824, i.e. +2%), and the most reliable on REGN targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

71% of analysts rate it a buy (Buy consensus, 17 ratings) — a sign of market conviction.
The most reliable firm on REGN, B of A Securities (80% hit rate, 15 scored calls), targets $860 (call made on January 7, 2026, maturing on January 7, 2027) (+6%) in its most recent call.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 17 ratings, 5 are neutral.
Limited upside: the median target is only +2% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on REGN

Median target $824 (+2%) · 17 ratings · Buy consensus

Strong Buy00%

Buy1271%

Hold529%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Regeneron Pharmaceuticals now?

We won't decide for you. The facts: 71% of analysts rate it a buy, median target $824 (+2%), and B of A Securities (most reliable on REGN, 80%) targets $860. Weigh that against valuation (P/E ~20). This is not personalized advice.

Is it too late to invest in Regeneron Pharmaceuticals?

The stated upside is small: the median target ($824) sits just +2% from the price ($808) (most reliable on REGN: B of A Securities, 80%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Regeneron Pharmaceuticals still worth investing in?

It depends on the gap between the price ($808) and its estimated value: analysts target $824 on median (+2%), with 71% buys (most reliable on REGN: B of A Securities, 80%). Cross-check with their real reliability on REGN and the cautions above. Information, not advice.

What's the main risk in buying REGN?

The consensus is not unanimous: of 17 ratings, 5 are neutral.

→ Go deeper: the full Regeneron Pharmaceuticals profile (consensus, analyst reliability, price target, performance).